NASDAQ:CTKB
Cytek Biosciences, Inc. Common Stock
- Stock
Last Close
6.18
17/05 20:00
Market Cap
800.76M
Beta: -
Volume Today
541.75K
Avg: 1.13M
PE Ratio
−73.77
PFCF: −132.08
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | ||
|---|---|---|---|---|---|---|
net income | -16.83M - | 19.41M 215.36% | 3.03M 84.41% | 2.48M 17.94% | -12.15M 589.05% | |
depreciation and amortization | 309K - | 603K 95.15% | 1.24M 105.97% | 5.66M 355.64% | 9.23M 63.10% | |
deferred income tax | 1.74M - | 448K 74.31% | 4.83M - | |||
stock based compensation | 269K - | 611K 127.14% | 6.59M 977.91% | 16.59M 151.97% | 22.05M 32.86% | |
change in working capital | 1.16M - | -7.54M 750.78% | -8.65M 14.73% | -39.93M 361.81% | -10.51M 73.68% | |
accounts receivables | -12.61M - | 334K 102.65% | -12.37M 3,802.69% | -19.74M 59.65% | -7.33M 62.86% | |
inventory | -14.61M - | -5.70M 60.97% | -7.07M 23.91% | -17.65M 149.76% | 4.29M 124.28% | |
accounts payables | 1.21M - | -55K 104.53% | -256K 365.45% | 1.86M 827.34% | -1.78M 195.81% | |
other working capital | 27.17M - | -2.11M 107.77% | 11.04M 623.21% | -4.39M 139.77% | -5.68M 29.27% | |
other non cash items | 1.34M - | 323K 75.97% | 1.97M 510.84% | 2.96M 49.97% | -8.17M 376.11% | |
net cash provided by operating activities | -13.75M - | 15.16M 210.25% | 4.63M 69.45% | -12.23M 364.17% | 5.28M 143.18% | |
investments in property plant and equipment | -973K - | -1.55M 58.99% | -4.36M 182.09% | -9.87M 126.12% | -4.83M 51.08% | |
acquisitions net | -16.63M - | -45.13M - | ||||
purchases of investments | -46.04M - | -175.94M 282.13% | ||||
sales maturities of investments | 132M - | |||||
other investing activites | ||||||
net cash used for investing activites | -973K - | -1.55M 58.99% | -20.99M 1,257.01% | -55.91M 166.32% | -93.89M 67.94% | |
debt repayment | -1.31M - | -2.77M 111.60% | -50K 98.20% | -565K 1,030% | ||
common stock issued | 93K - | 119.83M 128,754.84% | 215.69M 79.99% | 1.20M 99.44% | 1.47M 21.93% | |
common stock repurchased | -209K - | -44.15M 21,024.88% | ||||
dividends paid | -209K - | -1.47M 602.39% | ||||
other financing activites | 93K - | 4.08M 4,289.25% | 642K 84.27% | 4.78M 644.08% | 2.90M 39.21% | |
net cash used provided by financing activities | 93K - | 122.61M 131,735.48% | 213.56M 74.18% | 5.51M 97.42% | -41.81M 858.43% | |
effect of forex changes on cash | -33K - | -587K 1,678.79% | 1.30M 321.98% | -2.49M 291.17% | -1.45M 41.99% | |
net change in cash | -14.66M - | 135.63M 1,025.16% | 198.50M 46.35% | -65.12M 132.81% | -131.87M 102.51% | |
cash at beginning of period | 45.15M - | 30.49M 32.47% | 166.12M 444.83% | 364.62M 119.49% | 299.50M 17.86% | |
cash at end of period | 30.49M - | 166.12M 444.83% | 364.62M 119.49% | 299.50M 17.86% | 167.63M 44.03% | |
operating cash flow | -13.75M - | 15.16M 210.25% | 4.63M 69.45% | -12.23M 364.17% | 5.28M 143.18% | |
capital expenditure | -973K - | -1.55M 58.99% | -4.36M 182.09% | -9.87M 126.12% | -4.83M 51.08% | |
free cash flow | -14.72M - | 13.61M 192.45% | 266K 98.05% | -22.10M 8,407.89% | 454K 102.05% |
All numbers in USD (except ratios and percentages)